Previous Close | 5.34 |
Open | 5.38 |
Bid | 4.69 x 100 |
Ask | 5.56 x 100 |
Day's Range | 5.38 - 5.78 |
52 Week Range | 4.03 - 8.96 |
Volume | |
Avg. Volume | 3,439,522 |
Market Cap | 1.119B |
Beta (5Y Monthly) | 1.96 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.07 |
Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 14.00 |
RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU) after beginning treatment with ORLADEYO. The study was presented in a poster at the 2024 International Society for Pharmacoeconomics and O
BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) defied analyst predictions to release its first-quarter results, which...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript May 6, 2024 BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, expectations were $-0.23. BCRX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome […]